Esperion therapeutics, inc.ESPR.US Overview

US StockHealthcare

(No presentation for ESPR)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ESPR Overall Performance

ESPR AI Analysis & Strategy

ESPR Recent Performance

Esperion therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

ESPR PowerScanner

ESPR Key Information

ESPR Valuation Metrics

ESPR Earnings Table

ESPR Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.